Reading the tape
NASDAQ: KURA
Kura Oncology, Inc.
Healthcare · Biotechnology
Market Cap
$821.05M
52w High
$12.49
52w Low
$5.45
P/E
-2.92
Volume
1.28M
Outstanding Shares
88.76M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 37.65%Revenue (TTM): 25.24%FCF (TTM): -152.82%
What changed
The stock rose 37.65% over the last year. Revenue grew 25.24% over the trailing twelve months. Operating margin moved from -358.55% to -449.94%. Free cash flow declined 152.82% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -449.94%. A decisive move in revenue — currently up 25.24% — would be the clearest signal to resolve the ambiguity.
Company profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.
CEOTroy Edward Wilson
SectorHealthcare
IndustryBiotechnology
Employees192
IPO dateSep 16, 2015
Valuation
Forward P/E—
EV/EBITDA-2.58
Enterprise value$782.31M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-67.83%
Gross margin94.56%▼0.08%vs FY2024
Operating margin-449.94%▼25.49%vs FY2024
ROE-160.03%▼280.46%vs FY2024
Analyst consensus
RatingBuy
Target price$27.33▲195.46%
14
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.88 · Revenue est $25.97M
View